Vestcor Inc Acquires 1,771 Shares of Medpace Holdings, Inc. $MEDP

Vestcor Inc raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 66.3% in the 4th quarter, HoldingsChannel reports. The firm owned 4,442 shares of the company’s stock after purchasing an additional 1,771 shares during the quarter. Vestcor Inc’s holdings in Medpace were worth $2,495,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Optiver Holding B.V. bought a new position in Medpace in the 3rd quarter valued at $27,000. Geneos Wealth Management Inc. raised its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in Medpace in the 4th quarter valued at $30,000. Elyxium Wealth LLC bought a new position in Medpace in the 4th quarter valued at $30,000. Finally, Quarry LP bought a new position in Medpace in the 3rd quarter valued at $35,000. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

MEDP stock opened at $454.25 on Monday. The company has a market cap of $12.97 billion, a P/E ratio of 28.55, a PEG ratio of 2.30 and a beta of 1.18. Medpace Holdings, Inc. has a twelve month low of $294.07 and a twelve month high of $628.92. The business has a fifty day moving average of $456.73 and a 200-day moving average of $508.39.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm’s quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the sale, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 20.50% of the stock is owned by insiders.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
• Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
• Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on MEDP shares. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price for the company in a research report on Friday, February 13th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and dropped their target price for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Finally, BMO Capital Markets dropped their target price on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $467.08.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.